EmbryoGlue®

Embryo transfer is one of the most sensitive and critical procedures in IVF treatment. At Embryoland we use EmbryoGlue® for all embryo transfers. EmbryoGlue® is a medium developed exclusively for embryo transfer and the only existing product with a proven implantation-enhancing effect.

EmbryoGlue® is a product developed to closely resemble the environment in the uterus at the time of implantation. It is not a glue in the common sense, but acts as a glue by increasing the chance of implantation of the embryo to the uterus. EmbryoGlue® is enriched with the carbohydrates and amino acids needed to support the embryo during transfer and implantation. It has a relatively high concentration of hyaluronan and also contains the safest protein source available, i.e. recombinant albumin.

Hyaluronan is a natural substance abundant in all tissues in the body, and the levels of hyaluronan increase in the uterus at the time of implantation. The uterine wall and the embryo have receptor sites for this molecule. It is thought that the hyaluronan in EmbryoGlue® acts like a bridge between the embryo and the uterus, having a glue-like effect. Also, the higher concentration of hyaluronan thickens the solution to be more similar to the consistency of the fluids in the uterus. This allows better mixing of the medium and uterine fluids and is believed to minimize drifting of the embryo.

All patients going through IVF procedures that result in a transfer can benefit from EmbryoGlue®. A literature study by the independent research institute “Cochrane Collaboration” covering all published results on the effects of increased hyaluronan during embryo transfer shows an increase in implantation rate compared to embryo transfer without hyaluronan. EmbryoGlue® is the only product available that is enriched with hyaluronan. Other studies have demonstrated a significant increase in the number of babies brought home for couples with a wide range of infertility diagnoses. EmbryoGlue® has been shown to be especially beneficial for patients above the age of 35, patients with previously failed implantation, and patients with unexplained infertility.